Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer

被引:8
|
作者
Wang, Qi-Wei [1 ]
Zhang, Xiao-Tian [2 ]
Lu, Ming [2 ]
Shen, Lin [2 ]
机构
[1] Liaoning Canc Hosp & Inst, Dept Gastrointestinal Canc, Med Oncol, Shenyang 110042, Liaoning, Peoples R China
[2] Peking Univ, Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res,Minist Educ, 52 Fucheng Rd, Beijing 100142, Peoples R China
关键词
Gastric cancer; T4bN1-3M0/TxN3bM0; Recurrence; Distant metastasis; Adjuvant chemotherapy; PHASE-III TRIAL; RANDOMIZED CONTROLLED-TRIAL; NEOADJUVANT CHEMOTHERAPY; OPEN-LABEL; SURGERY; CAPECITABINE; OXALIPLATIN; ESOPHAGEAL; S-1;
D O I
10.4251/wjgo.v10.i1.31
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
AIM To provide evidence regarding the postoperative treatment of patients with T4bN1-3M0/TxN3bM0 gastric cancer, for which guidelines have not been established. METHODS Patients who had undergone curative resection between 1996 and 2014 with a pathological stage of T4bN13M0/TxN3bM0 for gastric cancer were retrospectively analyzed; staging was based on the 7th edition of the American Joint Committee on Cancer staging system. The clinicopathological characteristics, administration of adjuvant chemotherapy, and patterns of recurrence were studied. Univariate and multivariate analyses of prognostic factors were conducted. The chemotherapeutic agents mainly included fluorouropyrimidine, platinum and taxanes, used as monotherapy, doublet, or triplet regimens. Patterns of first recurrence were categorized as locoregional recurrence, peritoneal dissemination, or distant metastasis. RESULTS The 5-year overall survival (OS) of the whole group (n = 176) was 16.8%, and the median OS was 25.7 mo (95% CI: 20.9-30.5). Lymphovascular invasion and a node positive rate (NPR) = 0.8 were associated with a poor prognosis (P = 0.01 and P = 0.048, respectively). One hundred forty-seven (83.5%) of the 176 patients eventually experienced recurrence; the most common pattern of the first recurrence was distant metastasis. The prognosis was best for patients with locoregional recurrence and worst for those with peritoneal dissemination. Twelve (6.8%) of the 176 patients did not receive adjuvant chemotherapy, while 164 (93.2%) patients received adjuvant chemotherapy. Combined chemotherapy, including doublet and triplet regimens, was associated with a better prognosis than monotherapy, with no significant difference in 5-year OS (17.5% vs 0%, P = 0.613). The triplet regimen showed no significant survival benefit compared with the doublet regimen for 5-year OS (18.5% vs 17.4%, P = 0.661). Thirty-nine (22.1%) patients received adjuvant chemotherapy for longer than six months; the median OS in patients who received adjuvant chemotherapy for longer than six months was 40.2 mo (95% CI: 30.6-48.2), significantly longer than the 21.6 mo (95% CI: 19.1-24.0) in patients who received adjuvant chemotherapy for less than six months (P = 0.001). CONCLUSION Patients with T4bN1-3M0/TxN3bM0 gastric cancer showed a poor prognosis and a high risk of distant metastasis. Adjuvant chemotherapy for longer than six months improved outcomes for them.
引用
收藏
页码:31 / 39
页数:9
相关论文
共 50 条
  • [21] Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort
    Shen, Kaiwen
    Yao, Longdi
    Zhu, Jingyuan
    Gu, Ximing
    Wang, Jie
    Qian, Wei
    Zheng, Zhijian
    Fu, Deyuan
    Wu, Song
    BMC CANCER, 2022, 22 (01)
  • [22] Indications for adjuvant chemotherapy in patients with pT1N1M0 gastric cancer: a single-center experience
    Peng Jin
    Xiaoyan Ji
    Shuai Ma
    Wenzhe Kang
    Hao Liu
    Yang Li
    Fuhai Ma
    Haitao Hu
    Weikun Li
    Yantao Tian
    Journal of Cancer Research and Clinical Oncology, 2021, 147 : 561 - 568
  • [23] The Impact of Venous Invasion on the Postoperative Recurrence of pT1-3N0cM0 Gastric Cancer
    Imai, Yasuo
    Kurata, Yoshihiro
    Ichinose, Masanori
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (05):
  • [24] Is There Any Role of Adjuvant Chemotherapy for T3N0M0 or T1N2M0 Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System?
    Kyung-Goo Lee
    Hyuk-Joon Lee
    Seung-Young Oh
    Jun-Young Yang
    Hye-Seong Ahn
    Yun-Suhk Suh
    Seong-Ho Kong
    Tae-Yong Kim
    Do-Youn Oh
    Seock-Ah Im
    Kuhn Uk Lee
    Woo Ho Kim
    Yung-Jue Bang
    Han-Kwang Yang
    Annals of Surgical Oncology, 2016, 23 : 1234 - 1243
  • [25] The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy
    Fu, Wen-Fen
    Chen, Qing-Xia
    Wang, Xiao-Xiao
    Zhang, Jie
    Song, Chuan-Gui
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [26] Oncologic Outcomes of Patients With Resected T3N0M0 Non-small Cell Lung Cancer
    Marques, Edouard
    Kennedy, Kevin F.
    Giroux, Dorothy J.
    Cilento, Vanessa B.
    Nishimura, Katherine K.
    Fang, Wentao
    Figueroa, Paula Ugalde
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2023, 35 (04) : 796 - 804
  • [27] Patients with T4N0 and T1-3N1 colon cancer and a high preoperative carcinoembryonic antigen level benefit from adjuvant chemotherapy with oxaliplatin for 6 months
    Inoue, Hiroyuki
    Shimizu, Hiroki
    Kuriu, Yoshiaki
    Arita, Tomohiro
    Nanishi, Kenji
    Kiuchi, Jun
    Ohashi, Takuma
    Yamamoto, Yusuke
    Konishi, Hirotaka
    Morimura, Ryo
    Shiozaki, Atsushi
    Ikoma, Hisashi
    Kubota, Takeshi
    Fujiwara, Hitoshi
    Otsuji, Eigo
    ONCOLOGY LETTERS, 2025, 29 (01)
  • [28] Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer
    Byung Woog Kang
    Jong Gwang Kim
    Yee Soo Chae
    Yoo Jin Lee
    Soo Jung Lee
    Joon Ho Moon
    Sang Kyun Sohn
    Min Kyu Jung
    Seong Woo Jeon
    Yun-Jin Jang
    Jongduk Seo
    Yong Hyun Lee
    Ohkyung Kwon
    Ho Young Chung
    Wansik Yu
    Investigational New Drugs, 2012, 30 : 1671 - 1675
  • [29] Impact of chemotherapy on prognosis of resectable pathological T3N0M0 esophageal cancer patients: a population-based study
    Gu, Xiang
    Ge, Yizhi
    Liu, Jia
    Ding, Qian
    Chu, Junfeng
    Tian, Guangyu
    Chen, Xiaojun
    FUTURE ONCOLOGY, 2021, 17 (30) : 3925 - 3940
  • [30] Cycle number of neoadjuvant chemotherapy might influence survival of patients with T1-4N2-3M0 nasopharyngeal carcinoma
    Wei, Jiawang
    Feng, Huixia
    Xiao, Weiwei
    Wang, Qiaoxuan
    Qiu, Bo
    Liu, Shiliang
    Deng, Meiling
    Lu, Lixia
    Chang, Hui
    Gao, Yuanhong
    CHINESE JOURNAL OF CANCER RESEARCH, 2018, 30 (01) : 51 - +